Logo image
Clinical Characteristics, Treatment, and Outcomes of Provoked Acute Cerebral Sinovenous Thrombosis in Patients <21 Years Old: Findings from the Kids-DOTT Multinational Trial
Journal article   Open access   Peer reviewed

Clinical Characteristics, Treatment, and Outcomes of Provoked Acute Cerebral Sinovenous Thrombosis in Patients <21 Years Old: Findings from the Kids-DOTT Multinational Trial

Gary M. Woods, Alexandra Miller, Maua Mosha, Christoph Male, Anupam Verma, Nicole Kucine, Christine Sabapathy, Kisha Beg, Sanjay Ahuja, Deepti Raybagkar, …
Research and practice in thrombosis and haemostasis, v 8(7), 102605
Oct 2024
url
https://doi.org/10.1016/j.rpth.2024.102605View
Published, Version of Record (VoR) Open

Abstract

intracranial pediatrics sinus thrombosis thrombosis venous thromboembolism
Prospective multicenter data on the treatment and outcomes of children with cerebral sinovenous thrombosis (CSVT) are limited. We aimed to describe the clinical characteristics, treatment strategies, and outcomes of patients with a first-episode of provoked acute CSVT enrolled in the Kids-DOTT trial and compare these features to those participants with non-CSVT venous thromboembolism (VTE). This was a subgroup analysis from the Kids-DOTT trial, a multinational randomized clinical trial on duration of anticoagulation for provoked acute VTE in patients <21 years. Patient and thrombus characteristics, treatments, and outcomes for patients diagnosed with CSVT were compared to patients with non-CSVT VTE. CSVT was diagnosed in 75/532 (14%), 25 of whom received 6 weeks of anticoagulant treatment and 50 received 3 or more months. When compared to non-CSVT VTE, CSVT was more likely to occur in neonates and young children, was associated with infection in general and acute head/neck infection in particular, and less likely to be central venous catheter-related. No patient in either group developed symptomatic recurrent VTE or clinically relevant bleeding and there was no significant difference in rates of complete thrombus resolution between the two treatment durations. CSVT is most common in neonates and young children and those with acute head and neck infections. A six-week anticoagulation treatment course appears to be safe (no clinically relevant bleeding) and effective (no difference in symptomatic recurrent VTE) for acute provoked pediatric CSVT. Nevertheless, given the nature of a subpopulation analysis, these findings should be interpreted with caution. •Data on treatment and outcomes of cerebral sinovenous thrombosis (CSVT) in children are limited•This is a subgroup (CSVT) analysis from the Kids-DOTT trial•CSVT is most common in neonates and young children and with head and neck infections•Six-weeks of anticoagulation appears to be safe and effecitve for acute provoked pediatric CSVT

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Hematology
Peripheral Vascular Disease
Logo image